Combination therapy • Preclinical
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • KIF5B (Kinesin Family Member 5B) • MDM2 (E3 ubiquitin protein ligase) • TRIM33 (Tripartite Motif Containing 33) • ANXA5 (Annexin A5)
|
TP53 mutation • EGFR exon 19 deletion • TP53 wild-type • MDM2 amplification • RET mutation • KRAS G12S
|
MSK-IMPACT
|
Mekinist (trametinib) • Lumakras (sotorasib) • Retevmo (selpercatinib) • Tabrecta (capmatinib) • milademetan (RAIN-32)